Respiratory Syncytial Virus (RSV)

RSV Prevention Guidelines in UAE

Long acting Monoclonal Antibody is now mandatory for all infants in UAE

Healthcare Resource Utilization and Direct Medical Costs of RSV Infection in Children Under Five Years in Saudi Arabia

An overview of the latest Saudi evidence presented at ESPID 2026.

Epidemiology and Healthcare Burden Attributable to Laboratory-Confirmed RSV Cases Among Children Under Five Years Old in Saudi Arabia

An overview of the latest Saudi evidence presented at ESPID 2026.

Real-World Effectiveness of Nirsevimab

The NIRSE-GAL study is an ongoing population-based, prospective, longitudinal study conducted in Galicia, Spain. It includes infants eligible to receive nirsevimab and evaluates its impact on RSV-related outcomes in both inpatient and outpatient healthcare settings.

Evidence on Nirsevimab: Sustained Impact Across Two RSV Seasons

Drawing on data NirseGAL, this page provides healthcare professionals with evidence-based insights into nirsevimab's sustained protective impact across  two consecutive RSV seasons

Expanding RSV Protection in Kuwait

Summary of Kuwait’s updated RSV prevention policy

Healthcare Utilization and Economic Burden of Pediatric Lower Respiratory Tract Infections Across Five Tertiary Hospitals in Saudi Arabia

Healthcare Utilization and Economic Burden of Pediatric Lower Respiratory Tract Infections Across Five Tertiary Hospitals in Saudi Arabia

Healthcare Utilization and Economic Burden of RSV in Saudi Arabia

A Ministry of National Guard Facilities Analysis

Nirsevimab FAQs

Immunization, Protection, Administration and Safety

RWE data on Nirsevimab and RSV preF vaccine

Real‑world evidence (RWE) provides valuable insights into the effectiveness, safety, and use of RSV preventive strategies beyond clinical trials. This data support informed decision‑making and optimize the implementation of RSV prevention strategies in real‑world settings

Ensuring overall RSV prevention in every individual

Dr. Alia Podcast

Kuwait taking the lead in RSV protection for all infants in the Middle east

Podcast Dr. Dana Hajan

Nirsevimab RWD Metanalysis

Nirsevimab Metanalysis Real world data

RSV Burden in Jazan

Five Years’ Experience with Respiratory Syncytial Virus Among Hospitalized Patients: A Retrospective Study from Jazan, Saudi Arabia

Beyond High-Risk: Expanding RSV Protection for Newborns and Infants

Dr. Ali AlMudeer

New horizon of RSV lower respiratory tract disease LRTD in infants

Direct experiences of local implementation approaches—especially for infants born outside RSV season—and the impact of RSV immunization programs on public health systems

RSV History

RSV

All Infant Protection

All infants need protection from RSV, RSV is a leading cause of hospitalization in all infants

RSV Burden in Infants

Nirsevimab International Recommendation

International recommendations for Beyfortus® (nirsevimab) highlighting global guidance and expert consensus on RSV prevention in infants and vulnerable populations.

Rattle

Rattle is a global network of RSV experts that leverages up-to-date scientific content

Implementing Beyfortus successfully

Saudi initiatives on Bronchiolitis Recommendations

The first choice of RSV prevention is Nirsevimab; alternatively, palivizumab is to be considered in case of unavailability of Nirsevimab.